Osteoarthritis

You have full text access to this OnlineOpen article

Effect of hyaluronic acid in symptomatic hip osteoarthritis: A multicenter, randomized, placebo-controlled trial†

  1. Pascal Richette1,
  2. Philippe Ravaud2,‡,
  3. Thierry Conrozier3,§,
  4. Liana Euller-Ziegler4,
  5. Bernard Mazières5,
  6. Yves Maugars6,
  7. Denis Mulleman7,
  8. Pierre Clerson8,¶,
  9. Xavier Chevalier9,‖,*

Article first published online: 26 FEB 2009

DOI: 10.1002/art.24301

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 3, pages 824–830, March 2009

Additional Information

How to Cite

Richette, P., Ravaud, P., Conrozier, T., Euller-Ziegler, L., Mazières, B., Maugars, Y., Mulleman, D., Clerson, P. and Chevalier, X. (2009), Effect of hyaluronic acid in symptomatic hip osteoarthritis: A multicenter, randomized, placebo-controlled trial. Arthritis & Rheumatism, 60: 824–830. doi: 10.1002/art.24301

Author Information

  1. 1

    Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France

  2. 2

    INSERM U738, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France

  3. 3

    CHU Hôpital Lyon Sud, Pierre Bénite, France

  4. 4

    CHU Hôpital Archet I, Nice, France

  5. 5

    CHU Hôpital Rangueil, Toulouse, France

  6. 6

    CHU Hôtel Dieu, Nantes, France

  7. 7

    Hopital Trousseau, Tours, France

  8. 8

    Orgametric, Roubaix, France

  9. 9

    Hôpital Henri-Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France

  1. ‡

    Dr. Ravaud has received consulting fees, speaking fees, and/or honoraria from Servier, Roche, Daiichi Sankyo, Pfizer, Sanofi, Schering-Plough, and Almirall (less than $10,000 each).

  2. §

    Dr. Conrozier has received consulting fees, speaking fees, and/or honoraria from Genome and Bristol-Myers Squibb (less than $10,000 each) and from Pfizer and Smith & Nephew (more than $10,000 each).

  3. Dr. Clerson has received consulting fees, speaking fees, and/or honoraria from Daiichi Sankyo, Actelion, Janssen, Takeda, and Bayer Schering (more than $10,000 each).

  4. ‖

    Dr. Chevalier has received consulting fees, speaking fees, and/or honoraria from Expanscience, Pfizer, Genzyme, Servier, Sankyo, Rottapharma, and Fidia (less than $10,000 each).

*Department of Rheumatology, Hôpital Henri-Mondor, 94010 Créteil Cedex, France

  1. †

    ClinicalTrials.gov identifier: NCT00330135.

Publication History

  1. Issue published online: 26 FEB 2009
  2. Article first published online: 26 FEB 2009
  3. Manuscript Accepted: 7 NOV 2008
  4. Manuscript Received: 16 MAY 2008

Funded by

  • Daiichi Sankyo France

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (85K)

REFERENCES

  • 1
    Felson DT. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev 1988; 10: 1–28.
  • 2
    Ingvarsson T, Hagglund G, Lohmander LS. Prevalence of hip osteoarthritis in Iceland. Ann Rheum Dis 1999; 58: 201–7.
  • 3
    Roux C, Saraux A, Mazieres B, Pouchot J, Morvan J, Fautrel B, et al, on behalf of the KHOALA Osteoarthritis Group. Screening for hip and knee osteoarthritis in the general population: predictive value of a questionnaire and prevalence estimates. Ann Rheum Dis 2008; 67: 1406–11.
  • 4
    Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137–62.
  • 5
    Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669–81.
  • 6
    American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905–15.
    Direct Link:
  • 7
    Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003; 5: 54–67.
  • 8
    Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee [review]. Cochrane Database Syst Rev 2006 Apr 19; (2): CD005321.
  • 9
    Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003; 290: 3115–21.
  • 10
    Felson DT, Anderson JJ. Hyaluronate sodium injections for osteoarthritis: hope, hype, and hard truths. Arch Intern Med 2002; 162: 245–7.
  • 11
    Conaghan PG, Dickson J, Grant RL, on behalf of the Guideline Development Group. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ 2008; 336: 502–3.
  • 12
    Conrozier T, Vignon E. Is there evidence to support the inclusion of viscosupplementation in the treatment paradigm for patients with hip osteoarthritis? Clin Exp Rheumatol 2005; 23: 711–6.
  • 13
    Van den Bekerom MP, Lamme B, Sermon A, Mulier M. What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature. Arch Orthop Trauma Surg 2008; 128: 815–23.
  • 14
    Fernandez Lopez JC, Ruano-Ravina A. Efficacy and safety of intraarticular hyaluronic acid in the treatment of hip osteoarthritis: a systematic review. Osteoarthritis Cartilage 2006; 14: 1306–11.
  • 15
    Qvistgaard E, Christensen R, Torp-Pedersen S, Bliddal H. Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis Cartilage 2006; 14: 163–70.
  • 16
    Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 2007; 57: 1410–8.
    Direct Link:
  • 17
    Morshed S, Huffman GR, Ries MD. Septic arthritis of the hip and intrapelvic abscess following intra-articular injection of hylan G-F 20: a case report. J Bone Joint Surg Am 2004; 86-A: 823–6.
  • 18
    Conrozier T, Bertin P, Bailleul F, Mathieu P, Charlot J, Vignon E, et al. Clinical response to intra-articular injections of hylan G-F 20 in symptomatic hip osteoarthritis: the OMERACT-OARSI criteria applied to the results of a pilot study. Joint Bone Spine 2006; 73: 705–9.
  • 19
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191–4.
  • 20
    Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34: 505–14.
    Direct Link:
  • 21
    Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16: 494–502.
  • 22
    Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000; 8: 395–403.
  • 23
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833–40.
  • 24
    Berg P, Olsson U. Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study. Clin Exp Rheumatol 2004; 22: 300–6.
  • 25
    Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 2004; 63: 1611–7.
  • 26
    Lambert RG, Hutchings EJ, Grace MG, Jhangri GS, Conner-Spady B, Maksymowych WP. Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2007; 56: 2278–87.
    Direct Link:
  • 27
    Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 1716–23.
  • 28
    Tikiz C, Unlu Z, Sener A, Efe M, Tuzun C. Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumatol 2005; 24: 244–50.
  • 29
    Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis: consensus development at OMERACT III. J Rheumatol 1997; 24: 799–802.
  • 30
    Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage 1996; 4: 217–43.
  • 31
    Migliore A, Tormenta S, Martin Martin LS, Iannessi F, Massafra U, Carloni E, et al. The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. Clin Rheumatol 2006; 25: 389–93.
  • 32
    Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004; 12: 389–99.
View Full Article (HTML) Get PDF (85K)